论文部分内容阅读
为探讨急性白血病(AL)患者骨髓单个核细胞膜CD133-2的表达及其临床意义,采用免疫荧光标记和流式细胞仪测定164例AL患者骨髓单个核细胞膜CD133-2的表达。结果发现(1)AL患者骨髓单个核细胞膜CD133-2表达水平为19.8%(0.48%～88.29%),正常对照组骨髓单个核细胞膜CD133-2表达水平为0.48%(0.05%～0.89%),两者比较有显著性差异(P<0.01);(2)急性淋巴细胞性白血病(ALL)患者中骨髓单个核细胞膜CD133-2高表达阳性率的病例占55.26%(21/38),急性髓性白血病(AML)患者中骨髓单个核细胞膜CD133-2高表达阳性率的病例占45.24%(57/126)两者比较无显著性差异,急性白血病患者中各FAB亚型的CD133-2表达无显著性差异;(3)AL患者CD133-2阳性表达组的完全缓解率(CR)明显低于CD133-2阴性表达组(34.6%vs75.6%,P<0.01)。CD133-2在AML及ALL细胞呈现表达,明显高于正常对照,提示CD133-2的表达可能是AL的一个不良预后因素。
To investigate the expression of CD133-2 in bone marrow mononuclear cells of patients with acute leukemia (AL) and its clinical significance, the expression of CD133-2 in bone marrow mononuclear cells of 164 patients with AL was detected by immunofluorescence staining and flow cytometry. The results showed that: (1) The expression of CD133-2 in bone marrow mononuclear cell membrane was 19.8% (0.48% ~ 88.29%) in AL patients, and 0.48% (0.05% -0.89%) in mononuclear cells of normal control group, (2) The positive rate of CD133-2 in mononuclear cells of acute myeloid leukemia (ALL) was 55.26% (21/38) in patients with acute lymphoblastic leukemia (ALL) The positive rate of CD133-2 in the bone marrow mononuclear cells in patients with leukemia (AML) was 45.24% (57/126). There was no significant difference between the two groups in the expression of CD133-2 in patients with acute leukemia (3) The complete remission rate (CR) of CD133-2 positive expression group was significantly lower than that of CD133-2 negative expression group (34.6% vs75.6%, P <0.01). CD133-2 expression in AML and ALL cells was significantly higher than the normal control, suggesting that CD133-2 expression may be a negative prognostic factor for AL.